Chronic Total Occlusions of Coronary Arteries Clinical Trial
Official title:
Quality of Life Assessment in Patients With Coronary Artery Chronic Total Occlusion: Randomized Comparison of Optimal Medical Therapy and Percutaneous Coronary Intervention
Verified date | April 2020 |
Source | Clinical Centre of Serbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Several meta analysis comparing successful Percutaneous Coronary Intervention of Chronic
Total Occlusion (PCI-CTO) with unsuccessful PCI-CTO showed that there is significant
reduction in short-term and long-term mortality. To our knowledge till today no prospective
randomized trial compared percutaneous revascularization of CTO with optimal medical therapy.
For this reason quality of live improvement is one of the most important indications for
revascularization in elective patients with CTO. In contemporary literature Seattle Angina
Questionnaire (SAQ) is a psychometrically solid disease-specific instrument designed to
assess the functional status of patients with angina. It comprises 19 questions that quantify
five clinically relevant domains: physical limitation, angina stability, angina frequency,
treatment satisfaction and disease perception/quality of life.
In this open prospective study patients with CTO of coronary artery will be randomized in two
groups: first - patients with percutaneous coronary intervention of chronic total occlusion
with optimal medical therapy and second group - patients with only optimal medical therapy
(control group). Primary endpoint will be quality of life and secondary endpoints will be
mayor adverse cardiovascular events (MACE). All patients will complete Seattle Angina
Questionnaire before randomization and after 6 months of follow-up.
Status | Completed |
Enrollment | 100 |
Est. completion date | December 31, 2017 |
Est. primary completion date | November 30, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - CTO of coronary artery (TIMI 0 flow) - a) Stabile angina and/or b) evidence of ischemia in the territory of the CTO and/or c) evidence of viable myocardium in the CTO territory - target coronary artery with a reference diameter of 2.5 mm Exclusion Criteria: - acute myocardial infarction in past month - contraindications for dual antiplatelet therapy in future 12 months - contraindications for drug eluting stents (DES) - informed consent not signed - CTO in bypass graft - EF <20 % - Dementia - Patient not available for follow-up - CVI or TIA in past 6 months - Patients with: 1. neutropenia (<1000 /mm3) in past two weeks 2. thrombocytopenia (<100 000/mm3) 3. AST, ALT, alkaline phosphatase >1.5x the upper limit of normal 4. serum creatine >2 mg/dL (>180 µmol/L) - Patients with allergy to iodine contrast that cannot be treated medically - Life expectancy not longer than one year - Patients with bleeding diathesis or coagulopathy or will refuse transfusions. |
Country | Name | City | State |
---|---|---|---|
Serbia | Clinical Centre os Serbia | Belgrade |
Lead Sponsor | Collaborator |
---|---|
Clinical Centre of Serbia |
Serbia,
Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, Gannot S, Samuel M, Weisbrod M, Bierstone D, Sparkes JD, Wright GA, Strauss BH. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012 Mar 13;59(11):991-7. doi: 10.1016/j.jacc.2011.12.007. — View Citation
Godino C, Sharp AS, Carlino M, Colombo A. Crossing CTOs-the tips, tricks, and specialist kit that can mean the difference between success and failure. Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1019-46. doi: 10.1002/ccd.22161. — View Citation
Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GB, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK; COURAGE Trial Research Group. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2010 Mar 30;55(13):1348-58. doi: 10.1016/j.jacc.2009.10.062. — View Citation
Pancholy SB, Boruah P, Ahmed I, Kwan T, Patel TM, Saito S. Meta-analysis of effect on mortality of percutaneous recanalization of coronary chronic total occlusions using a stent-based strategy. Am J Cardiol. 2013 Feb 15;111(4):521-5. doi: 10.1016/j.amjcard.2012.10.034. Review. — View Citation
Prasad A, Rihal CS, Lennon RJ, Wiste HJ, Singh M, Holmes DR Jr. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol. 2007 Apr 17;49(15):1611-1618. doi: 10.1016/j.jacc.2006.12.040. Epub 2007 Apr 2. — View Citation
Rathore S, Matsuo H, Terashima M, Kinoshita Y, Kimura M, Tsuchikane E, Nasu K, Ehara M, Asakura Y, Katoh O, Suzuki T. Procedural and in-hospital outcomes after percutaneous coronary intervention for chronic total occlusions of coronary arteries 2002 to 2008: impact of novel guidewire techniques. JACC Cardiovasc Interv. 2009 Jun;2(6):489-97. doi: 10.1016/j.jcin.2009.04.008. — View Citation
Saito S. Progress in angioplasty for chronic total occlusions again. Catheter Cardiovasc Interv. 2010 Nov 15;76(6):850-1. doi: 10.1002/ccd.22847. — View Citation
Sianos G, Werner GS, Galassi AR, Papafaklis MI, Escaned J, Hildick-Smith D, Christiansen EH, Gershlick A, Carlino M, Karlas A, Konstantinidis NV, Tomasello SD, Di Mario C, Reifart N; EuroCTO Club. Recanalisation of chronic total coronary occlusions: 2012 consensus document from the EuroCTO club. EuroIntervention. 2012 May 15;8(1):139-45. doi: 10.4244/EIJV8I1A21. Review. — View Citation
Werner GS, Bahrmann P, Mutschke O, Emig U, Betge S, Ferrari M, Figulla HR. Determinants of target vessel failure in chronic total coronary occlusions after stent implantation. The influence of collateral function and coronary hemodynamics. J Am Coll Cardiol. 2003 Jul 16;42(2):219-25. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Health related quality of life | Seattle Angina Questionnaire | 6 months | |
Secondary | all cause death, Major Adverse Cardiac Event (MACE) including: Acute Myocardial Infarction - AMI, repeated revascularisation | 6 months |